0.85
-0.0213(-2.45%)
Currency In USD
| Previous Close | 0.87 |
| Open | 0.87 |
| Day High | 0.89 |
| Day Low | 0.83 |
| 52-Week High | 737.5 |
| 52-Week Low | 0.83 |
| Volume | 186,320 |
| Average Volume | 2.93M |
| Market Cap | 3.1M |
| PE | 0 |
| EPS | -5,217.5 |
| Moving Average 50 Days | 1.6 |
| Moving Average 200 Days | 96.52 |
| Change | -0.02 |
If you invested $1000 in Windtree Therapeutics, Inc. (WINT) 10 years ago, it would be worth $0 as of May 09, 2025 at a share price of $0.849. Whereas If you bought $1000 worth of Windtree Therapeutics, Inc. (WINT) shares 5 years ago, it would be worth $0.03 as of May 09, 2025 at a share price of $0.849.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US
GlobeNewswire Inc.
May 06, 2025 12:18 PM GMT
If istaroxime is granted the new chemical entity designation from FDA, it could provide 7.5 years of U.S. exclusivity and additionally the istaroxime U.S. issued method of use patent protects until 2039 for its planned initial indication in cardiogen
Windtree Announces Strategic Transaction to Drive Revenue Generation in Support of Ongoing Therapeutic Pipeline Development
GlobeNewswire Inc.
May 01, 2025 12:30 PM GMT
Initial transaction provides the right to buy the target asset which may provide consistent revenue to Windtree while it continues to develop its biotech pipeline drug candidatesWARRINGTON, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutic
Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules
GlobeNewswire Inc.
Mar 24, 2025 12:00 PM GMT
WARRINGTON, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech and advancing early and late-stage innovative t